Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan? in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Start Date30 Jul 2025

Sponsor / Collaborator-

NCT04564092

/ CompletedPhase 1

A Phase 1, Non-randomised, Noncomparative, Open-label Study to Assess the Safety, Biodistribution, and Internal Radiation Dosimetry of a Single Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers

This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I) injection in Chinese Healthy Volunteers.

Start Date13 May 2021

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+1]

EUCTR2019-000247-27-FR

/ Not yet recruitingPhase 3

Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP

Start Date31 Mar 2021

Sponsor / Collaborator

Zionexa US Corp.

100 Clinical Results associated with Ioflupane-I-123

100 Translational Medicine associated with Ioflupane-I-123

100 Patents (Medical) associated with Ioflupane-I-123

342

Literatures (Medical) associated with Ioflupane-I-123

01 Jul 2025·Revista espanola de medicina nuclear e imagen molecular

Justification and impact of SPECT ¹²³I-FP-CIT use in the differential diagnosis and management of movement disorders (MD) in a national referral hospital

Article

Author: Mitjavila Casanovas, M ; Ruiz Solís, S ; Canales Rodríguez, L

AIM:

To evaluate the adequacy and impact of ¹²³I-FP-CIT SPECT in the diagnosis and management of MD according to clinical guidelines.

PATIENTS AND METHODS:

Retrospective study involving 249 patients with suspected parkinsonism (PK) of uncertain origin. All underwent ¹²³I-FP-CIT SPECT and had a clinical follow-up of exceeding 12 months. Requests were classified based on their adherence to clinical guidelines. Variables analyzed included sex, age, justification for the request, management after SPECT, and final diagnosis.

RESULTS:

91.57% of the requests were appropriate, while 8.43% did not adhere to the guidelines. Diagnosis changed in 48.6% of cases and management in 70.68% after the scan, especially in inconclusive cases and initiation of therapy. General neurologists evaluated more cases and made more appropriate requests (96.3% vs 76.67%; p<0.001). However, MD specialists, despite less appropriate use of the guidelines, achieved a higher number of conclusive diagnoses in complex cases.

CONCLUSION:

¹²³I-FP-CIT SPECT has significant clinical impact when used in accordance with clinical guidelines, improving the diagnosis and management of MD. Unjustified scans reduce its utility. Collaboration between general neurologists and MD specialists is fundamental; the latter, although showing less adherence to guidelines in requesting the test, achieve a higher number of conclusive diagnoses in complex cases.

04 Jun 2025·CURRENT TOPICS IN MEDICINAL CHEMISTRY

Neurological Inflammation in Parkinsonism: Current PrognosticativeDiagnostics and Pitfalls

Article

Author: Gopinath, Subash C.B. ; Sasidharan, Sreenivasan ; Chen, Yeng ; Fakhri, Makram A. ; Lakshmipriya, Thangavel ; Salim, Evan T.

Parkinson's disease (PD) is a persistent neurological degenerative condition that cansignificantly alter one's quality of life. This condition affects the substantia nigra, the region of thebrain that contains dopamine-producing neurons. It is a disorder of the central nervous system thatarises when nerve cells, or neurons, in this brain area are damaged or die. Norepinephrine, anotherchemical messenger that aids in controlling primary physiological processes, such as heart rate andblood pressure, is also deficient in PD patients. The symptoms of PD can interfere with daily activitiesand include fatigue, walking difficulties, limb rigidity, and loss of smell. Researchers are strivingto identify a reliable biomarker for Parkinson's disease. Currently, the Food and Drug Administrationhas approved the radiotracer I-123-ioflupane injection followed by scanning (DATscan-SPECT) for precise analysis. To diagnose Parkinson's disease early, researchers are developingpredictive diagnostic techniques using various biomarkers. The right biosensor can recommend thebest personalized course of action to slow the progression of Parkinson's disease. This review highlightsthe strong performance of diagnostic biomarkers for Parkinson's disease and emphasizes theeffectiveness of the common immuno-, apta- and DNA-sensors for their efficient implementationsfor different biomarkers. Further, it also discusses the potential advantages and drawbacks associatedwith detection methods for improving high-performance diagnostics.

01 Mar 2025·Brain disorders (Amsterdam, Netherlands)

A proposal of visual assessment of serotonergic deficits in parkinsonian syndromes: An 123I-FP-CIT SPECT study

Author: Yoshioka, Masaru ; Sugimura, Yoko ; Takeda, Atsushi ; Totsune, Tomoko ; Tanaka, Hiroyasu ; Takahashi, Toshiaki ; Oizumi, Hideki ; Baba, Toru ; Nagamatsu, Ken-ichi

¹²³I-FP-CIT, primarily used for imaging dopamine transporters in the nigrostriatal pathway, also shows some affinity for the serotonin transporter (SERT), which is predominantly distributed in the raphe nuclei in the brainstem.Recent imaging studies have demonstrated that compared with Parkinson′s disease (PD), atypical parkinsonian syndromes (PS) exhibit pronounced SERT reduction using semiquant. methods.However, the utility of qual. visual assessment methods for SERT has been poorly discussed to date.The aims of this study were to propose a visual assessment grading system of brainstem ¹²³I-FP-CIT uptake and investigate the ability of this method to differentiate PD from PS.We analyzed the imaging data of 97 parkinsonian patients who underwent ¹²³I-FP-CIT SPECT.First, we graded ¹²³I-FP-CIT uptake in the midbrain and pons with a 4-degree scale and analyzed the interrater agreement of our grading method.Next, we compared the visual grading data of the PD (n = 59) and PS (n = 11) groups and analyzed the diagnostic utility of the qual. visual assessment method.The interrater agreement of the visual grading of ¹²³I-FP-CIT uptake among the three raters was moderate (Fleiss′ Kappa 0.480 for midbrain, 0.488 for pons).The patterns of ¹²³I-FP-CIT uptake in the pons differed significantly between patients with PD and PS (p = 0.035).The visual assessment-based classification showed 81.8 % sensitivity, 61.0 % specificity, 28.1 % pos. predictive value, and 94.7 % neg. predictive value in distinguishing PS from PD.Visual assessment of SERT abnormalities with ¹²³I-FP-CIT may contribute to differentiating PD and PS in clin. settings.

News (Medical) associated with Ioflupane-I-123

30 Sep 2025

·www.einpresswire.com

April - June 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Acetaminophen-containing products Anaphylactic reaction FDA is evaluating the need for regulatory action. Aptryxol (desvenlafaxine) DaTscan (ioflupane I 123 injection) Desvenlafaxine extended-release tablets Effexor XR (venlafaxine extended-release) capsules Pristiq (desvenlafaxine) extended-release tablets Venlafaxine (venlafaxine hydrochloride) extended-release tablets False positive radioisotope investigation test result potentially secondary to a drug interaction with venlafaxine FDA is evaluating the need for regulatory action. Barium sulfate-containing products Entero Vu 24% (barium sulfate) oral suspension E-Z-Disk (barium sulfate) tablets Liquid E-Z-Paque (barium sulfate) oral suspension Readi-Cat 2 (barium sulfate) oral suspension Readi-Cat 2 Smoothie (barium sulfate) oral suspension Taglitol V (barium sulfate) oral suspension Varibar Honey (barium sulfate) oral suspension Varibar Nectar (barium sulfate) oral suspension Varibar Pudding (barium sulfate) oral paste Varibar Thin Honey (barium sulfate) oral suspension Varibar Thin Liquid (barium sulfate) oral suspension Anaphylactic reaction FDA is evaluating the need for regulatory action. Blincyto (blinatumomab) for injection Columvi (glofitamab-gxbm) injection Elrexfio (elranatamab-bcmm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Lunsumio (mosunetuzumab-axgb) injection Talvey (talquetamab-tgvs) injection Tecvayli (teclistamab-cqyv) injection Progressive multifocal leukoencephalopathy FDA is evaluating the need for regulatory action. BRAF kinase inhibitors Braftovi (encorafenib) capsules Ojemda (tovorafenib) for oral suspension; tablets Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablets Gingival hypertrophy FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Acute hepatic failure The "Warnings and Precautions" section of the labeling was updated in August 2025 to include information about liver injury. Example: Briumvi labeling Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection Central nervous system infection FDA is evaluating the need for regulatory action. Crexont (carbidopa and levodopa) extended-release capsules Dhivy (carbidopa and levodopa) tablets Duopa (carbidopa and levodopa) enteral suspension Rytary (carbidopa and levodopa) extended-release capsules Sinemet (carbidopa and levodopa) tablets Sinemet CR (carbidopa and levodopa) sustained-release tablets Stalevo (carbidopa, levodopa and entacapone) tablets Vyalev (foscarbidopa and foslevodopa) injection Seizure FDA is evaluating the need for regulatory action. Crysvita (burosumab-twza) injection Hypercalcemia The "Dosage and Administration", "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in August 2025 to include information about hypercalcemia. Crysvita labeling Dexmedetomidine-containing products Dexmedetomidine injection Precedex (dexmedetomidine hydrochloride) injection Igalmi (dexmedetomidine) sublingual film Diabetes insipidus FDA is evaluating the need for regulatory action. Dupixent (dupilumab) injection Ocular infections, irritations, and inflammation FDA is evaluating the need for regulatory action. Eprontia (topiramate) oral solution Qudexy XR (topiramate) extended-release capsules Qsymia (phentermine and topiramate) extended-release capsules Topamax (topiramate) tablets Topamax Sprinkle (topiramate) capsules Trokendi XR (topiramate) extended-release capsules Hypersensitivity FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Chylothorax FDA is evaluating the need for regulatory action. Glucagon-like peptide-1 (GLP-1) receptor agonists Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection Intestinal obstruction and fecal impaction FDA is evaluating the need for regulatory action. Imbruvica (ibrutinib) capsules; tablets; oral suspension Nail and nail bed conditions (excluding infections and infestations) FDA is evaluating the need for regulatory action. MEK inhibitors Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Koselugo (selumetinib) capsules Gingival hypertrophy FDA is evaluating the need for regulatory action. Neffy (epinephrine nasal spray) Product storage error FDA is evaluating the need for regulatory action. Nurtec ODT (rimegepant) orally disintegrating tablets Zavzpret (zavegepant) nasal spray Anaphylactic reaction The "Contraindications" and "Warnings and Precautions" sections of the labeling were updated in August 2025 to include information about hypersensitivity reactions, including anaphylaxis. Example: Nurtec ODT labeling Rozlytrek (entrectinib) capsules; oral pellets Brugada syndrome FDA is evaluating the need for regulatory action. Sodium-glucose cotransporter-2 (SGLT2) inhibitors Fournier's gangrene FDA is evaluating the need for regulatory action. Teriparatide injection (a particular generic product) Device malfunction FDA is evaluating the need for regulatory action. Vizamyl (flutemetamol F18 injection) Anaphylactic reaction The "Warnings and Precautions" section of the labeling was updated in June 2025 to include information about anaphylaxis and other serious hypersensitivity reactions. Vizamyl labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

30 Mar 2025

·investor.gehealthcare.com

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease. CHICAGO--(BUSINESS WIRE)--Mar. 31, 2025-- GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.” NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP. The Company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter.

AcquisitionDiagnostic Reagents

30 Nov 2024

·www.businesswire.com

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

CHALFONT ST GILES, England--([BUSINESS WIRE](https://www.businesswire.com/))--GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals. NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research. GE HealthCare has held its 50% stake in NMP since acquiring Amersham plc in 2004 and holds three positions on its Board of Directors. Kevin O’Neill, President & CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said: “As the third largest pharmaceutical market in the world1, and amongst the leading countries by number of cyclotrons2, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond. This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.” Hiroshi Ueda, Executive Vise President, Sumitomo Chemical, said: “We are proud of our 50-year relationship with NMP and our partnership with GE HealthCare to ensure patients in Japan could benefit from access to molecular imaging. At a time of exciting developments in the industry, following its discussions with Sumitomo Chemical, we believe GE HealthCare is the best owner to enable NMP to continue its successful growth journey. I would like to recognize NMP’s leadership and talented team for their significant achievements to date and their commitment to patients.” As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiotracers used across major patient care areas. The recent U.S. FDA approval of GE HealthCare’s first-of-its-kind PET radiopharmaceutical, Flyrcado™ (flurpiridaz F 18 injection), its in-licensing of Phase II FAPI assets and broadening theranostics offerings are all examples of the company’s commitment to novel diagnostics that are shaping the future of molecular imaging to drive improved patient outcomes. GE HealthCare’s PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second. The Company expects this transaction to be neutral to Adjusted EPS3,4 in year one and accretive thereafter. GE HealthCare was advised by Solomon Partners Securities, LLC. **Forward-Looking Statements** This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. **About GE HealthCare Technologies Inc.** GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=LinkedIn&index=1&md5=8b71aacc0c8a28615a479f49839b2367), [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FGEHealthCare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=X&index=2&md5=5d3e010c5b6762aa437c9ed721a93fae), [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Facebook&index=3&md5=afb7811bf3d186531a1f0195046c19a3), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Instagram&index=4&md5=3e9a372d9f56b271b045aed2f9b1ed7e), and [Insights](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Insights&index=5&md5=528c8409aca3aa77dc9faa2bd39a47a3) for the latest news, or visit our website [https://www.gehealthcare.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.gehealthcare.com&index=6&md5=149ee377d64e90ca25044fcc3fff9335) for more information. 1 [https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&index=7&md5=469d2d595d8ea2691b2fbf21839f9df1), accessed on October 29, 2024 2 [https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&index=8&md5=2bd260a4b0f14e662995bcc8256bab6e), accessed on October 29, 2024 3 See our latest [earnings release](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.gehealthcare.com%2Fnode%2F10446%2Fpdf&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=earnings+release&index=9&md5=200cc703972627cdc567e9acdbf69787) dated October 30, 2024 for the definition of Adjusted EPS. 4 Non-GAAP financial measure

AcquisitionDrug Approval

100 Deals associated with Ioflupane-I-123

External Link

KEGG	Wiki	ATC	Drug Bank
D10014	Ioflupane-I-123	V09AB03	DB08824

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lewy Body Disease	United States	GE Healthcare, Inc.	01 Nov 2022
Diagnostic agents	Japan	Nihon Medi-Physics Co., Ltd.	20 Sep 2013
Essential Tremor	South Korea	Samyoung Unitech Co. Ltd.	15 Apr 2011
Parkinson Disease	South Korea	Samyoung Unitech Co. Ltd.	15 Apr 2011
Parkinsonian Disorders	European Union	GE Healthcare B.V.	27 Jul 2000
Parkinsonian Disorders	Iceland	GE Healthcare B.V.	27 Jul 2000
Parkinsonian Disorders	Liechtenstein	GE Healthcare B.V.	27 Jul 2000
Parkinsonian Disorders	Norway	GE Healthcare B.V.	27 Jul 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple System Atrophy	Phase 3	China	GE Healthcare Holdings, Inc.	28 Jun 2020
Multiple System Atrophy	Phase 3	China	GE Healthcare B.V.	28 Jun 2020
Multiple System Atrophy	Phase 3	China	GE Healthcare (Shanghai) Co. Ltd.	28 Jun 2020
Multiple System Atrophy	Phase 3	China	GE Healthcare Pvt Ltd.	28 Jun 2020
Supranuclear Palsy, Progressive	Phase 3	China	GE Healthcare B.V.	28 Jun 2020
Supranuclear Palsy, Progressive	Phase 3	China	GE Healthcare Pvt Ltd.	28 Jun 2020
Supranuclear Palsy, Progressive	Phase 3	China	GE Healthcare (Shanghai) Co. Ltd.	28 Jun 2020
Supranuclear Palsy, Progressive	Phase 3	China	GE Healthcare Holdings, Inc.	28 Jun 2020
Alzheimer Disease	Phase 3	Germany	GE Healthcare Holdings, Inc.	01 Nov 2003
Dementia, Vascular	Phase 3	Germany	GE Healthcare Holdings, Inc.	01 Nov 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04193527 (CTgov)	Phase 3	Essential Tremor \| Supranuclear Palsy, Progressive \| Multiple System Atrophy ... View more	172	DaTSCAN™ ioflupane (123I) (DaTSCAN™ Ioflupane: Participants With Parkinsonian Syndrome (PS))	uqaqxlauqp = ccbeckfmle ubpzvuuwqo (vnafbyomvj, oofndidsan - rxawnuyaxb) View more	-	16 Oct 2023
				DaTSCAN™ ioflupane (123I) (DaTSCAN™ Ioflupane: Participants With Essential Tremor (ET))	gyjpbfrngt = xerjhdxoyu smedliqlyf (fglclwcqoo, zxumclywry - wkqysdsgbe) View more
NCT04564092 (CTgov)	Phase 1	-	9	DaTSCAN™ Ioflupane (123I) Injection	afnrvqpony = qplvlimcqv rfbnvrupvz (qppnxjgfvo, raavhpnxii - mbqkfluxuc) View more	-	02 Aug 2023
AAN2022	Not Applicable	REM Sleep Behavior Disorder	34	123I-FP-CIT	nbdelixflx(psmbgqrago) = wrcuinzjql fytgdjbkpe (oxjppbjqum ) View more	-	03 May 2022
				123I-FP-CIT	nbdelixflx(psmbgqrago) = ordhijebir fytgdjbkpe (oxjppbjqum ) View more
NCT01141023 (PPMI, EAN2019)	Phase 2	Parkinson Disease [123I]FP-CIT SPECT \| MDS-UPDRS	389	[123I]FP-CIT SPECT (PD patients with drooling)	yzunpichmc(xvdanajhyu): HR = 1.823 (95% CI, 1.176 - 2.827), P-Value = 0.007	Positive	27 Jun 2019
				[123I]FP-CIT SPECT (PD patients without drooling)
NCT01141023 (PPMI, EAN2019)	Phase 2	Parkinson Disease [123I]FP-CIT SPECT	390	[123I]FP-CIT (PD patients with gait impairment)	wwbpmnvpbc(xytiabverc) = rfuaalymnu wgvpfkctme (qhmbneurck )	Positive	27 Jun 2019
NCT01141023 (PPMI, AAN2015)	Phase 2	Parkinson Disease dopamine transporter (DAT)	167	123-I Ioflupane SPECT	acjksljudr(qmgifnfelm) = gfbdjeapsk ezlcvsswgz (udbqgciuwo )	Positive	06 Apr 2015
NCT01141023 (PPMI, SNMMI2014)	Phase 2	Parkinson Disease dopamine transporter SPECT imaging	298	123-I Ioflupane SPECT	hnthpoufdm(lavufknyou) = qruimrkifz fhbhwqfaud (ohlroruogj, 15.6%)	Positive	05 Nov 2014
				123-I I-Ioflupane (PD subjects with 3 SPECT scans)	hnthpoufdm(lavufknyou) = iykqneucsx fhbhwqfaud (ohlroruogj, 15.6%)
AAIC 12008 \| AAIC 22008	Not Applicable	Lewy Body Disease 123I-FP-CIT SPECT	325	123I-FP-CIT SPECT	rtkcacyppn(ovpcopfhib) = jautwhceep rjzakndlfs (tlufyvwtez ) View more	Positive	01 Jul 2008

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ioflupane-I-123

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation